|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistic, 2011: The impact of eliminating socioeconomic and
racial disparities on premature cancer deaths. Ca Cancer J Clin.
61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh SR: Gastric cancer stem cells: A
novel therapeutic target. Cancer Lett. 338:110–119. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao Y, Feng F and Zhou YN: Stem cells in
gastric cancer. World J Gastroenterol. 21:112–123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roboz GJ and Guzman M: Acute myeloid
leukemia stem cells: Seek and destroy. Expert Rev Hematol.
2:663–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Valent P: Targeting of leukemia-initiating
cells to develop curative drug therapies: Straightforward but
nontrivial concept. Current Cancer Drug Targets. 11:56–71. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Korkaya H and Wicha MS: Selective
targeting of cancer stem cells. BioDrugs. 21:299–310. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu L, Gibson P, Currle DS, Tong Y,
Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW
and Gilbertson RJ: Prominin 1 marks intestinal stem cells that are
susceptible to neoplastic transformation. Nature. 457:603–607.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barker N, Ridgway RA, Van Es JH, van de
Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR,
Sansom OJ and Clevers H: Crypt stem cells as the cells-of-origin of
intestinal cancer. Nature. 457:608–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cozzio A, Passegué E, Ayton PM, Karsunky
H, Cleary ML and Weissman IL: Similar MLL-associated leukemias
arising from self-renewing stem cells and short-lived myeloid
progenitors. Genes Dev. 17:3029–3035. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeung K, Seitz T, Li S, Janosch P,
McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, et
al: Suppression of Raf-1 kinase activity and MAP kinase signalling
by RKIP. nature. 401:173–177. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chatterjee D, Bai Y, Wang Z, Beach S, Mott
S, Roy R, Braastad C, Sun Y, Mukhopadhyay A and Aggarwal BB: RKIP
sensitizes prostate and breast cancer cells to drug-induced
apoptosis. J Biol Chem. 279:17515–17523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Mulla F, Hagan S, Behbehani AI, Bitar
MS, George SS, Going JJ, García JJ, Scott L, Fyfe N, Murray GI and
Kolch W: Raf kinase inhibitor protein expression in a survival
analysis of colorectal cancer patients. J Clin Oncol. 24:5672–5679.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Keller ET, Fu Z, Yeung K and Brennan M:
Raf kinase inhibitor protein: A prostate cancer metastasis
suppressor gene. Cancer Lett. 207:131–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hagan S, Al-Mulla F, Mallon E, Oien K,
Ferrier R, Gusterson B, García JJ and Kolch W: Reduction of Raf-1
kinase inhibitor protein expression correlates with breast cancer
metastasis. Clin Cancer Res. 11:7392–7397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schuierer MM, Bataille F, Hagan S, Kolch W
and Bosserhoff A-K: Reduction in Raf kinase inhibitor protein
expression is associated with increased Ras-extracellular
signal-regulated kinase signaling in melanoma cell lines. Cancer
Res. 64:5186–5192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nyström T, Yang J and Molin M:
Peroxiredoxins, gerontogenes linking aging to genome instability
and cancer. Genes Dev. 26:2001–2008. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szatrowski TP and Nathan CF: Production of
large amounts of hydrogen peroxide by human tumor cells. Cancer
Res. 51:794–798. 1991.PubMed/NCBI
|
|
21
|
Yamamoto M, Furihata C, Ogiu T, Tsukamoto
T, Inada Ki, Hirano K and Tatematsu M: Independent variation in
susceptibilities of six different mouse strains to induction of
pepsinogen-altered pyloric glands and gastric tumor
intestinalization by N-methyl-N-nitrosourea. Cancer Lett.
179:121–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayakawa Y, Fox JG, Gonda T, Worthley DL,
Muthupalani S and Wang TC: Mouse models of gastric cancer. Cancers
(Basel). 5:92–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamidouche Z, Haÿ E, Vaudin P, Charbord P,
Schüle R, Marie PJ and Fromigué O: FHL2 mediates
dexamethasone-induced mesenchymal cell differentiation into
osteoblasts by activating Wnt/beta-catenin signaling-dependent
Runx2 expression. FASEB J. 22:3813–3822. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Waterborg JH: The Lowry method for protein
quantitation. protein Protoc Handb. 1–9. 2002.
|
|
25
|
Abate-Shen C: Deregulated homeobox gene
expression in cancer: Cause or consequence? Nat Re Cancer.
2:777–785. 2002. View
Article : Google Scholar
|
|
26
|
Yu S, Yang M and Nam KT: Mouse models of
gastric carcinogenesis. J Gastric Cancer. 14:67–86. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jang BI, Li Y, Graham DY and Cen P: The
role of CD44 in the pathogenesis, diagnosis and therapy of gastric
cancer. Gut Liver. 5:397–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ghaffarzadehgan K, Jafarzadeh M, Raziee
HR, Sima HR, Esmaili-Shandiz E, Hosseinnezhad H, Taghizadeh-Kermani
A, Moaven O and Bahrani M: Expression of cell adhesion molecule
CD44 in gastric adenocarcinoma and its prognostic importance. World
J Gastroenterol. 14:6376–6381. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nosrati A, Naghshvar F and Khanari S:
Cancer stem cell markers CD44, CD133 in primary gastric
adenocarcinoma. Int J Mol Cell Med. 3:279–286. 2014.PubMed/NCBI
|
|
30
|
Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y,
Qin S and Wang Q: Expression of sox2 and oct4 and their clinical
significance in human non-small-cell lung cancer. Int J Mol Sci.
13:7663–7675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park YH, Kim SU, Lee BK, Kim HS, Song IS,
Shin HJ, Han YH, Chang KT, Kim JM, Lee DS, et al: Prx I suppresses
K-ras-driven lung tumorigenesis by opposing redox-sensitive
ERK/cyclin D1 pathway. Antioxid Redox Signal. 19:482–496. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Diao S, Zhang Jf, Wang H, He ML, Lin MC,
Chen Y and Kung HF: Proteomic identification of microRNA-122a
target proteins in hepatocellular carcinoma. Proteomics.
10:3723–3731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takaishi S, Okumura T, Tu S, Wang SS,
Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Beshir AB, Ren G, Magpusao AN, Barone LM,
Yeung KC and Fenteany G: Raf kinase inhibitor protein suppresses
nuclear factor-κB-dependent cancer cell invasion through negative
regulation of matrix metalloproteinase expression. Cancer Lett.
299:137–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jin DZ, Jung HC, Kim JM, Kim JS, Song IS
and Kim CY: Establishment of BALB/c mice model infected with
Helicobacter pylori. Korean J Intern Med. 14:55–63. 1999.
View Article : Google Scholar : PubMed/NCBI
|
